(4-Carboxybutyl)triphenylphosphonium bromide

• Catalog No.: 157945
• CAS Number: 17814-85-6
• M. F.: C23H24BrO2P
• M. W.: 443.313221
• Purity: 98%

SYNONYMS

• Title: (4-羧丁基)三苯基溴化膦
• IUPAC name: (4-carboxybutyl)triphenylphosphanium bromide
• IUPAC Traditional name: (4-carboxybutyl)triphenylphosphanium bromide
• Synonyms: 5-(Triphenylphosphonio)pentanoic acid bromide; NSC 147756; Carboxybutyltriphenylphosphonium bromide

DATABASE IDS

• PubChem SID: 24849711
• EC Number: 241-782-5
• MDL Number: MFCD00011906
• CAS Number: 17814-85-6
• Beilstein Number: 3586477

PROPERTIES

• Linear Formula: (C6H5)3P(Br)(CH2)4COOH
• Purity: 98%
• Melting Point: 204-207 °C(lit.)
• GHS Signal Word: Warning
• GHS Hazard statements: H315-H319-H335
• European Hazard Symbols: Irritant (Xi)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• GHS Precautionary statements: P261-P305 + P351 + P338
• Risk Statements: 36/37/38
• Safety Statements: 26-36
• German water hazard class: 3

DETAILS

Description (English)

Packaging
10, 50, 250 g in poly bottle
Application

• Used as a platform for delivery of pro-apoptotic peptides into the mitochondria of tumor cells1Reactant for preparation of:
• Ring skeletons via ring closing metathesis and double bond migration ring closing metathesis reactions2
• Methyl alkenyl quinolones as antimycobacterial agents3
• Prostaglandins and their drug analogs via Gold-catalyzed Meyer-Schuster rearrangement4
• Diphenylmethylpiperazines as N-type calcium channel blockers as potential therapeutic agents5
• Folate receptor-specific glycinamide ribonucleotide formyltransferase (GARFTase) inhibitors with antitumor activity6
• Cycloalkylidene alkanols with antileishmanial activity, via Wittig reaction7

Description (简体中文)

包装
10, 50, 250 g in poly bottle
Application

• Used as a platform for delivery of pro-apoptotic peptides into the mitochondria of tumor cells1Reactant for preparation of:
• Ring skeletons via ring closing metathesis and double bond migration ring closing metathesis reactions2
• Methyl alkenyl quinolones as antimycobacterial agents3
• Prostaglandins and their drug analogs via Gold-catalyzed Meyer-Schuster rearrangement4
• Diphenylmethylpiperazines as N-type calcium channel blockers as potential therapeutic agents5
• Folate receptor-specific glycinamide ribonucleotide formyltransferase (GARFTase) inhibitors with antitumor activity6
• Cycloalkylidene alkanols with antileishmanial activity, via Wittig reaction7